ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO), a clinical-stage biotechnology company focused on cancer therapies, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for June 3, 2026 at 5:30 PM ET and will be available via webcast with a 90-day replay.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
In the Jun 1 session, ALXO declined 5.26%, reflecting a notable negative market reaction. Argus tracked a trough of -5.6% from its starting point during tracking.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Earnings and update | Positive | +11.2% | Q1 2026 results, pipeline updates, and financing details. |
| May 07 | Clinical data update | Positive | -10.5% | Promising Phase 1b/2 breast cancer responses and survival data. |
| Apr 30 | Conference presentation | Positive | +7.6% | Announcement of CD47 biomarker data presentation at ESMO Breast 2026. |
| Apr 17 | Inducement option grant | Neutral | +4.8% | Large stock option grant to new development and operations leader. |
| Apr 13 | Executive appointment | Positive | +2.9% | Appointment of new Chief Development and Operating Officer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally seen positive price reactions, with one notable divergence on strong clinical data.
Over the last few months, ALXO has reported several catalysts: Q1 2026 earnings and financing on May 8 with a +11.23% move, strong Phase 1b/2 breast cancer data on May 7 that oddly saw a -10.53% reaction, and biomarker data conference positioning on Apr 30 with a +7.59% move. Leadership changes and inducement grants in mid‑April also drew modest gains. Today’s conference participation fits the pattern of visibility-building rather than a major clinical or financial inflection.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.
The details of the meeting are as follows:
2026 Jefferies Global Healthcare Conference in New York
Format: Fireside Chat Presentation
Date: June 3, 2026
Time: 5:30 PM ET
Webcast link: Available here
The webcast of the 2026 Jefferies Global Healthcare Conference presentation can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replay of the webcast will be archived for up to 90 days following the presentation date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
